Oncoimmunology

SCI SCIE

国际简称：ONCOIMMUNOLOGY 参考译名：肿瘤免疫学

主要研究方向：ONCOLOGYIMMUNOLOGY-IMMUNOLOGY 非预警期刊审稿周期：24 Weeks

《肿瘤免疫学》(Oncoimmunology)是一本由Landes Bioscience出版的以ONCOLOGYIMMUNOLOGY-IMMUNOLOGY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

2区中科院分区
Q1 JCR分区
116 年发文量
6.2 IF影响因子
开放是否OA
49 H-index
2012 创刊年份
12 issues/year 出版周期
English 出版语言

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.

OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.

[ 查看全部 ]

投稿咨询加急咨询

Oncoimmunology期刊信息

ISSN：2162-402X
出版语言：English
是否OA：开放
E-ISSN：2162-402X
出版地区：UNITED STATES
是否预警：否
出版商：Landes Bioscience
出版周期：12 issues/year
创刊时间：2012
开源占比：0.9969
Gold OA文章占比：100.00%
OA被引用占比：0.0951...
出版国人文章占比：0.13
出版撤稿占比：0
研究类文章占比：95.69%

Oncoimmunology CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

12.1

2.438

1.099

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q1	41 / 428	90%
大类：Medicine 小类：Immunology and Allergy	Q1	31 / 234	86%
大类：Medicine 小类：Immunology	Q1	35 / 243	85%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Oncoimmunology中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	2区	ONCOLOGY 肿瘤学 IMMUNOLOGY 免疫学	2区 2区

Oncoimmunology JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：IMMUNOLOGY	SCIE	Q1	36 / 183	80.6
学科：ONCOLOGY	SCIE	Q1	60 / 333	82.1
学科：IMMUNOLOGY	SCIE	Q1	26 / 183	86.07
学科：ONCOLOGY	SCIE	Q1	49 / 333	85.44

Oncoimmunology历年数据统计

影响因子

中科院分区

Oncoimmunology中国学者发文选摘

1、Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cance
Author: Lecoester, Benoit; Xie, Yaoyao; Sun, Xushan; Renaudin, Adeline; Ndao, Babacar; Boullerot, Laura; Malfroy, Marine; Arnier, Rudy; Boisson, Cyril; Laheurte, Caroline; Meurisse, Aurelia; Chevalier, Cedric; Vulquin, Noemie; Thibouw, David; Benhmida, Salim; Pernot, Mandy; Vernerey, Dewi; Mirjolet, Celine; Guo, Junming; Boustani, Jihane; Adotevi, Olivier

Journal: ONCOIMMUNOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1080/2162402X.2026.2635806
2、Patritumab deruxtecan induces immunogenic cell deat
Author: Forveille, Sabrina; Zhao, Liwei; Sauvat, Allan; Cerrato, Giulia; Leduc, Marion; Doffe, Flora; Pan, Yuhong; Liu, Peng; Kroemer, Guido; Kepp, Oliver

Journal: ONCOIMMUNOLOGY. 2025; Vol. 14, Issue 1, pp. -. DOI: 10.1080/2162402X.2025.2514050
3、PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cance
Author: Fang, Tian; Xia, Yu; Li, Ying; Xu, Sen; Li, Huayi; Wang, Siyuan; Huang, Pu; Qian, Yiyu; Jin, Ping; Jin, Ning; Xu, Cheng; Wang, Zhen; Xiong, Xiaoming; Wang, Mengjie; Zhou, Dongchen; Wang, Ya; Li, Xiaoting; Xu, Tao; Zhang, Qi; Liu, Dan; Fang, Yong; Zhao, Guang-Nian; Gao, Qinglei

Journal: ONCOIMMUNOLOGY. 2025; Vol. 14, Issue 1, pp. -. DOI: 10.1080/2162402X.2025.2516294
4、Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellular carcinom
Author: Chen, Jing; Sun, Hong-Wei; Wang, Run-Zheng; Zhang, Yun-Fei; Li, Wen-Jiao; Wang, Yong-Kui; Wang, Hao; Jia, Miao-Miao; Xu, Qing-Xia; Zhuang, Hao; Xue, Ning

Journal: ONCOIMMUNOLOGY. 2025; Vol. 14, Issue 1, pp. -. DOI: 10.1080/2162402X.2025.2497172
5、TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8+ T cell functio
Author: Wang, Ran; Xu, Jiefang; Cheng, Shipeng; Ling, Zhiyang; Sonam, Wangmo; Yang, Jichao; Jin, Fuquan; Wen, Jing; Lu, Xiao; Ma, Liyan; Zhang, Yaguang; Sun, Xiaoyu; Yi, Chunyan; Sun, Bing

Journal: ONCOIMMUNOLOGY. 2025; Vol. 14, Issue 1, pp. -. DOI: 10.1080/2162402X.2025.2497171
6、Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSC
Author: Zhang, Xuyao; Feng, Zijie; Haran, Annapurna Pranatharthi; Hua, Xianxin

Journal: ONCOIMMUNOLOGY. 2025; Vol. 14, Issue 1, pp. -. DOI: 10.1080/2162402X.2025.2458843